Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacillus clausii combined with oral rehydration therapy (ORT) is a therapeutic approach utilized for the management of acute diarrhea, primarily in infants and children. Bacillus clausii is a spore-forming, polyantibiotic-resistant probiotic bacterium that promotes the restoration of the intestinal microflora balance, while oral rehydration therapy replenishes essential fluids and electrolytes to prevent or treat dehydration. This combination approach, frequently administered alongside zinc supplementation as part of standard pediatric care, has been evaluated in Phase 3 clinical trials to determine its clinical efficacy in reducing the duration and severity of diarrheal episodes compared to standard rehydration alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bacillus clausii + oral rehydration therapy.